Ocugen Inc

Ocugen Inc. reported a 20% increase in revenue to $1.4 million in Q2 2025, beating expectations and marking a strong performance for the clinical-stage biopharmaceutical company.

Ocugen Inc. reported a GAAP EPS of -$0.05 and $1.48 million in revenue for its first quarter 2025, exceeding earnings expectations despite a decline in revenue compared to the previous year.